Business Context and Reporting Period
Company: Isis Pharmaceuticals, Inc. (now Ionis Pharmaceuticals)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Isis is a biopharmaceutical company focused on developing RNA-based therapeutics, primarily using antisense technology to inhibit disease-causing proteins. The company's pipeline includes 11 antisense products in various stages of development targeting cancer, inflammatory diseases, viral infections, and metabolic disorders. The company also operates the Ibis program, developing biosensor technology for infectious disease identification, largely funded by U.S. government contracts.
Key Financial Metrics
| Metric | 2003 | 2002 |
|---|---|---|
| Total Revenue | $49.99 million | $80.18 million |
| Net Loss | $(95.69) million | $(73.30) million |
| Net Loss Per Share (Basic/Diluted) | $(1.73) | $(1.35) |
| Research & Development Expenses | $116.96 million | $124.07 million |
| Cash, Cash Equivalents & Short-Term Investments | $215.50 million | $289.35 million |
| Working Capital | $194.00 million | $244.23 million |
| Total Debt & Obligations | $250.63 million | $233.83 million |
| Accumulated Deficit | $(555.58) million | $(459.89) million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 38% ($30.2 million) compared to 2002. This was primarily driven by the conclusion of collaborations with Elan (Orasense and HepaSense) in late 2002 and reduced revenue from the clinical development of Affinitak.
- Increased Net Loss: Net loss applicable to common stock increased by approximately 31% ($22.4 million) due to higher operating losses, a $2.4 million non-cash impairment loss on equity investments (ATL and Hybridon), and the absence of a $5.0 million gain on debt prepayment recorded in 2002.
- Debt Restructuring: In December 2003, the company secured a $32.0 million term loan from Silicon Valley Bank to retire higher-interest convertible partner debt. Additionally, Eli Lilly waived repayment of a $21.2 million manufacturing loan in June 2003.
- Restructuring Costs: The company incurred $1.8 million in restructuring charges in 2003 following disappointing Phase III results for Affinitak, compared to $1.4 million in 2002 related to the GeneTrove program reorganization.
Guidance, Outlook, and Risks
- Clinical Pipeline Status:
- Affinitak (Lung Cancer): Phase III results in March 2003 were insufficient to support a single-study New Drug Application (NDA). A decision on future development depends on a second Phase III trial, with results expected in the second half of 2004.
- Alicaforsen (Crohn's Disease): Two Phase III trials are ongoing in North America and Europe, with data expected in the second half of 2004.
- ISIS 104838 (Rheumatoid Arthritis): Phase II data reported in late 2003 showed disease response; an additional Phase II trial is planned for 2004.
- Liquidity Outlook: Management believes available cash, investments, and committed contractual payments will be sufficient to meet requirements for at least the next 36 months. However, additional financing may be required if commercialization goals are not met.
- Key Risks:
- Failure to obtain regulatory approval for drug candidates.
- Dependence on collaborative partners (e.g., Lilly, Amgen) for funding and commercialization.
- High degree of uncertainty regarding the commercial success of the TIGER biosensor technology.
- Significant accumulated losses and history of operating losses.
- Recent Developments (Post-Period): In March 2004, the company entered a strategic alliance with Alnylam Pharmaceuticals for RNAi therapeutics (including a $10 million equity investment) and secured a $19.5 million DARPA contract for TIGER biosensor development.
Investor Verification Checklist
- Affinitak Future: Verify the status and timeline of the second Phase III trial for Affinitak, as the first trial failed to meet primary endpoints.
- Liquidity Runway: Confirm the sufficiency of the $215.5 million cash balance against the $250.6 million in debt obligations and ongoing R&D burn rate.
- Revenue Concentration: Note that 62% of 2003 revenue came from a single customer (Eli Lilly), creating significant concentration risk.
- Government Contract Stability: Assess the risk of U.S. government contract termination for the Ibis/TIGER program, which accounts for 20% of revenue.
- Patent Portfolio Value: Review the valuation of the 1,300+ issued patents, particularly regarding the Macugen license with Eyetech/Pfizer, which offers potential future royalties but no guaranteed revenue.